Summary
The effects of prazosin and alphamethyldopa on blood lipids and lipoproteins were assessed in 20 patients with mild or moderate arterial hypertension. Parameters measured included serum cholesterol (CHO), triglycerides (TG), high density lipoprotein-cholesterol (HDL-CHO), insulin (I), glucose (G), and non-esterified fatty acids (NEFA). Prazosin — 4 mg/day for 6 weeks in hydrochlorothiazide-treated patients lowered blood pressure by 18.6/17.2 (systolic/diastolic pressure) mmHg. There was a significant decrease in CHO (−5.8%), in I (−16.5%), and in NEFA (−3.0%), and a significant increase in HDL-CHO (+15.5%). Alphamethyldopa 250–750 mg/day for 6 weeks in hydrochlorothiazide-treated patients lowered blood pressure by 18.8/14.6 (systolic/diastolic pressure) mmHg, accompanied by a non-significant decrease in CHO and TG, and significant increases in HDL-CHO (+10.3%), G (+8.5%) and NEFA (+6.4%). Thus, prazosin appears to have a more beneficial effect on blood lipids and lipoproteins than alphamethyldopa.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Veterans administration cooperative study group on antihypertensive agents (1970) Effect of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. J Am Med Assoc 213, 1143–1152
Brunzell JD, Miller NE (1981) Atherosclerosis in inherited and acquired disorders of plasma lipoprotein metabolism. In Miller NE, Lewis B (eds) Lipoproteins, atherosclerosis and Coronary heart disease. Elsevier, Amsterdam, pp 73–88
Rhoads GG, Gulbrandsen CL, Kagan A (1976) Serum lipoproteins and coronary heart disease in a population study of Hawaiian Japanese men. N Engl J Med 294, 293–298
Miller NE, Hammett F, Saltissi S (1980) Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J 282, 1741–1744
Ames RP, Hill P (1976) Elevation of serum lipid levels during diuretic therapy of hypertension. Am J Med 61, 748–757
Nilsson A, Hansson BC, Hökfelt B (1978) Beta-blockers and lipid metabolism. Br Med J 1: 986–988
Velasco M, Silva H, Morillo J, Pellicer R, Urbina A, Hernández-Pieretti O (1983) In: Velasco M (ed) Clinical pharmacology and therapeutics. Excerpta Medica, Amsterdam, pp 85–92
Leren P, Helgeland A, Holme I (1980) Effect of propanolol and prazosin on blood lipids. The Oslo Study. Lancet 2: 4–6
Kokubu T, Itoh I, Kurita H, Ochi T, Murata K, Yuba I (1982) Effect of prazosin on serum lipids. J Cardiovasc Pharmacol 4 (Suppl 2): S228-S232
Velasco M, Silva H, Morillo J, Pellicer R, Urbina-Quintana A, Hernández-Pieretti O (1982) Effect of prazosin on blood lipids and on thyroid function in hypertensive patients. J Cardiovasc Pharmacol 4 (Suppl 2): S225-S227
Stadtman TC (1957) In: Colowick SP, Kaplan NO (eds) Methods in enzymology, vol III. Academy Press, New York, pp 392–394
Burstein M, Scholnick HR, Morfin R (1970) Rapid method for isolation of lipoproteins from human serum by precipitation by polyanions. J Lipid Res 2: 583–595
Rautela GS, Liedtke RJ (1978) Automatic enzymic measurement of total cholesterol in serum. Clin Chem 24: 108–114
Dole VP (1956) Nonesterified acid determination. J Clin Invest 35: 150–154
Slein MW, Bergmeyer HV (1963) Method of enzymatic analysis. Ass Press New York, pp 117
Yalow RS, Berson SA (1960) Immunoassay of endogenous plasma renin in man. J Clin Invest 39: 1157–1160
Snedecor GW, Cochran WE (1971) Statistical methods, 6th edn. Iowa State University Press, Ames
Kather H, Simon B (1981) Adrenoceptor of the alpha 2 subtype mediating inhibition of the human fat cell adenylate cyclase. Eur J Clin Invest 11: 111–114
William-Olson T, Sellenius E, Bjorntorp P (1979) Differences in metabolic responses to B-adrenergic stimulation after propranolol or metoprolol administration. Acta Med Scand 205: 201–206
Johnson B (1982) The emerging problems of plasma lipid changes during antihypertensive therapy. J Cardiovas Pharmacol 4 (Suppl 2): S213-S221
Harms HH, Gooren L, Spoelstra AG (1978) Blockade of isoprenaline induced changes in plasma free fatty acids, immunoreactive insulin levels and plasma renin activity in healthy human subjects, by propranolol, pindolol, practolol, atenolol, metoprolol and acebutolol. Br J Clin Pharmacol 5: 19–26
Taskinen MR, Nikkila E (1979) Lipoproteins lipase activity of adipose tissue and skeletal muscle in insulin deficient human diabetes. Diabetologia 17: 351–356
Orosz L, Erdelyi G, Romics L (1973) Effect of insulin on plasma postheparine lipoprotein lipase activity in patients with cornonary sclerosis and in control subjects. Atherosclerosis 18: 265–275
Buse MG, Johnson AH, Kuperminc D, Buse J (1970) Effect of alpha-adrenergic blockade on insulin secretion in man. Metabolism 19: 219–226
Majid PA, Saxton C, Dykes JRW, Galvin MC, Taylor SH (1970) Autonomic control of insulin secretion and the treatment of heart failure. Br Med J 4: 328–330
Ames RP, Hill P (1982) Antihypertensive therapy and the risk of coronary heart disease. J Cardiovas Pharmacol 4 (Suppl 2): S206-S212
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Velasco, M., Silva, H., Feldstein, E. et al. Effects of prazosin and alphamethyldopa on blood lipids and lipoproteins in hypertensive patients. Eur J Clin Pharmacol 28, 513–516 (1985). https://doi.org/10.1007/BF00544060
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00544060